- Home
- NXRT vs SNDX Comparison
NXRT vs SNDX Comparison
Compare NXRT & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXRT
- SNDX
- Stock Information
- Founded
- NXRT 2014
- SNDX 2005
- Country
- NXRT United States
- SNDX United States
- Employees
- NXRT N/A
- SNDX N/A
- Industry
- NXRT Real Estate Investment Trusts
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- NXRT Real Estate
- SNDX Health Care
- Exchange
- NXRT Nasdaq
- SNDX Nasdaq
- Market Cap
- NXRT 1.2B
- SNDX 1.4B
- IPO Year
- NXRT N/A
- SNDX 2016
- Fundamental
- Price
- NXRT $43.49
- SNDX $13.40
- Analyst Decision
- NXRT Buy
- SNDX Strong Buy
- Analyst Count
- NXRT 5
- SNDX 11
- Target Price
- NXRT $49.00
- SNDX $37.64
- AVG Volume (30 Days)
- NXRT 91.8K
- SNDX 1.9M
- Earning Date
- NXRT 02-18-2025
- SNDX 11-05-2024
- Dividend Yield
- NXRT 4.52%
- SNDX N/A
- EPS Growth
- NXRT 54.64
- SNDX N/A
- EPS
- NXRT 1.77
- SNDX N/A
- Revenue
- NXRT $264,974,000.00
- SNDX $16,000,000.00
- Revenue This Year
- NXRT N/A
- SNDX N/A
- Revenue Next Year
- NXRT $0.54
- SNDX N/A
- P/E Ratio
- NXRT $25.24
- SNDX N/A
- Revenue Growth
- NXRT N/A
- SNDX N/A
- 52 Week Low
- NXRT $28.20
- SNDX $13.22
- 52 Week High
- NXRT $48.37
- SNDX $25.34
- Technical
- Relative Strength Index (RSI)
- NXRT 43.52
- SNDX 30.64
- Support Level
- NXRT $44.31
- SNDX $13.36
- Resistance Level
- NXRT $46.15
- SNDX $14.18
- Average True Range (ATR)
- NXRT 0.90
- SNDX 0.81
- MACD
- NXRT -0.30
- SNDX -0.18
- Stochastic Oscillator
- NXRT 14.08
- SNDX 11.32
About NXRT NexPoint Residential Trust Inc.
NexPoint Residential Trust Inc is a real estate investment trust company. Its objectives are to maximize the cash flow and value of properties owned, acquire properties with cash flow growth potential, provide quarterly cash distributions, and achieve long-term capital appreciation for stockholders. The company seeks to achieve these objectives through targeted management and a capex value-add program. It focuses on acquiring multifamily properties in markets with attractive job growth and household formation fundamentals predominantly in the Southeastern and Southwestern United States. The company generates revenue from the rental of multifamily properties.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.